Clinical Pharmacokinetics

, Volume 55, Issue 4, pp 409–418 | Cite as

The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations

  • Hirotoshi EchizenEmail author
Leading Article


Vonoprazan fumarate (Takecab®) is a first-in-class potassium-competitive acid blocker that has been available in the market in Japan since February 2015. Vonoprazan is administered orally at 20 mg once daily for the treatment of gastroduodenal ulcer, at 20 and 10 mg once daily for the treatment and secondary prevention of reflux esophagitis, respectively, at 10 mg once daily for the secondary prevention of low-dose aspirin- or non-steroidal anti-inflammatory drug-induced peptic ulcer, and at 20 mg twice daily in combination with clarithromycin and amoxicillin for the eradication of Helicobacter pylori. It inhibits H+,K+-ATPase activities in a reversible and potassium-competitive manner with a potency of inhibition approximately 350 times higher than the proton pump inhibitor, lansoprazole. Vonoprazan is absorbed rapidly and reaches maximum plasma concentration at 1.5–2.0 h after oral administration. Food has minimal effect on its intestinal absorption. Oral bioavailability in humans remains unknown. The plasma protein binding of vonoprazan is 80 % in healthy subjects. It distributes extensively into tissues with a mean apparent volume of distribution of 1050 L. Being a base with pKa of 9.6 and with acid-resistant properties, vonoprazan is highly concentrated in the acidic canaliculi of the gastric parietal cells and elicited an acid suppression effect for longer than 24 h after the administration of 20 mg. The mean apparent terminal half-life of the drug is approximately 7.7 h in healthy adults. Vonoprazan is metabolized to inactive metabolites mainly by cytochrome P450 (CYP)3A4 and to some extent by CYP2B6, CYP2C19, CYP2D6, and SULT2A1. A mass balance study showed that 59 and 8 % of the orally administered radioactivity was recovered in urine as metabolites and in an unchanged form, respectively, indicating extensive metabolism. Genetic polymorphism of CYP2C19 may influence drug exposure but only to a clinically insignificant extent (15–29 %), according to the population pharmacokinetic study performed in Japanese patients. When vonoprazan was co-administered with clarithromycin, the mean AUC from time 0 to time of the next dose (dosing interval) of vonoprazan and clarithromycin were increased by 1.8 and 1.5 times, respectively, compared with the corresponding control values, indicating mutual metabolic inhibition. The mean area under the curve from time zero to infinity obtained from patients with severe liver and renal dysfunction were elevated by 2.6 and 2.4 times, respectively, compared with healthy subjects, with no significant changes in plasma protein binding. Vonoprazan increases intragastric pH above 4.0 as early as 4 h after an oral dose of 20 mg, and the extensive anti-secretory effect is maintained up to 24 h post-dose. During repeated dosing of 20 mg once daily, the 24-h intragastric pH >4 holding time ratios were 63 and 83 % on days 1 and 7, respectively. Because vonoprazan elicited a more extensive gastric acid suppression than the proton pump inhibitor, lansoprazole, it also gave rise to two to three times greater serum gastrin concentrations as compared with lansoprazole. In pre-approval clinical studies for the treatment of acid-related disorders, mild to moderate adverse drug reactions (mostly constipation or diarrhea) occurred at frequencies of 8–17 %. Neither severe liver toxicity nor neuroendocrine tumor has been reported in patients receiving vonoprazan.


Clarithromycin Lansoprazole Reflux Esophagitis Atazanavir Gastroduodenal Ulcer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Compliance with Ethical Standards

Conflict of interest

The author declares no conflict of interest regarding the present article.


  1. 1.
    Soll AH, Achord JL, Bozymski G, Brooks S, Lanza F, Lyon D, Meyer G, Reinus J, Schuster M, Achord J, Ofman J, Glassman P, Laine L, Tytgat G, Walsh JH, Graham DY, Peterson WL. Medical treatment of peptic ulcer disease: practice guidelines. JAMA. 1996;275:622–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Axon A. Helicobacter pylori and public health. Helicobacter. 2014;19(Suppl 1):68–73.CrossRefPubMedGoogle Scholar
  3. 3.
    Fock KM, Ang TL, Bee LC, Lee EJD. Proton pump inhibitors. Clin Pharmacokinet. 2008;47:1–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Katz PO, Hatlebakk JG, Gstell DO. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole. Aliment Pharmacol Ther. 2000;14:709–14.CrossRefPubMedGoogle Scholar
  5. 5.
    Shaw MJ, Crawley JA. Improving health-related quality of life in gastro-oesophageal reflux disease. Drugs. 2003;63:2307–16.CrossRefPubMedGoogle Scholar
  6. 6.
    Cheng HC, Sheu BS. Intravenous proton pump inhibitors in the management for peptic ulcer bleeding: clinical benefits and limits. World J Gastrointest Endosc. 2011;3:49–56.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Furuta T, Sugimoto M, Shirai N. Individualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19. Mol Diagn Ther. 2012;16:223–34.CrossRefPubMedGoogle Scholar
  8. 8.
    Parsons ME, Keeling DJ. Novel approaches to the pharmacological blockade of gastric acid secretion. Expert Opin Investig Drugs. 2005;14:411–21.CrossRefPubMedGoogle Scholar
  9. 9.
    Chung IS, Choi MG, Park SH, et al. Revaprazan (Revanex®), a novel acid pump antagonist, for duodenal ulcer: results of a double-blind, randomized, parallel, multi-center phase III clinical trial. Korean J Gastrointest Endosc. 2005;31(1):17–24.Google Scholar
  10. 10.
    Chang R, Chung IS, Park SH, et al. Phase III clinical trial of revaprazan (Revanex®) for gastric ulcer. Korean J Gastrointest Endosc. 2007;34(6):312–9.Google Scholar
  11. 11.
    Jenkins H, Sakurai Y, Nishimura A, Okamoto H, Hibberd M, Jenkins R, Yoneyama T, Ashida K, Ogama Y, Warrington S. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015;41:636–48.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Umegaki E, Iwakiri K, Hiramatsu N, et al. A phase 3, randomized, double-blind, multicenter study to evaluate the efficacy and safety of TAK-438 (10 mg or 20 mg once-daily) compared to lansoprazole (15 mg once-daily) in a 24-week maintenance treatment for healed erosive esophagitis. Gastroenterology. 2014;146:S-738.CrossRefGoogle Scholar
  13. 13.
    Mizokami Y, Ashida K, Soen S, et al. TAK-438 versus lansoprazole 15 mg for secondary prevention of peptic ulcers associated with non-steroidal anti-inflammatory drug (NSAID) therapy: results of a phase 3 trial. Gastroenterology. 2014;146:S-739.CrossRefGoogle Scholar
  14. 14.
    Kawai T, Ashida K, Mizokami Y, et al. TAK-438 versus lansoprazole 15 mg for secondary prevention of peptic ulcers associated with low-dose aspirin therapy: results of a phase 3 trial. Gastroenterology. 2014;146:S-739.CrossRefGoogle Scholar
  15. 15.
    Murakami K, Sakurai Y, Shiino M, et al. A phase 3, double-blind study of a triple therapy with TAK-438, amoxicillin, and clarithromycin as first line eradication of H. pylori and a triple therapy with TAK-438, amoxicillin, and metronidazole as second line eradication of H. pylori. Gastroenterology. 2014;146:S-740.CrossRefGoogle Scholar
  16. 16.
    Iwakiri K, Umegaki E, Hiramatsu N, et al. A phase 3, randomized, double-blind, multicenter study to evaluate the efficacy and safety of TAK-438 (20 mg once-daily) compared to lansoprazole (30 mg once-daily) in patients with erosive esophagitis. Gastroenterology. 2014;146:S-741.CrossRefGoogle Scholar
  17. 17.
    Sakurai Y, Mori Y, Okamoto H, et al. A crossover study to evaluate the acid-inhibitory effect of a newly developed potassium-competitive acid blocker, vonoprazan, compared with esomeprazole or rabeprazole. Gastroenterology. 2015;148:S-620.CrossRefGoogle Scholar
  18. 18.
    Mizokami Y, Oda K, Saito K, et al. A phase 3, lansoprazole-controlled, long-term extension study to evaluate the safety and efficacy of vonoprazan (10 mg or 20 mg) for prevention of recurrent peptic ulcers during long-term therapy with non-steroidal anti-inflammatory drug (NSAID). Gastroenterology. 2015;148:S-88–S-89.CrossRefGoogle Scholar
  19. 19.
    Garnock-Jones KP. Vonoprazan: first global approval. Drugs. 2015;75:439–43.CrossRefPubMedGoogle Scholar
  20. 20.
    Drug approval review for vonoprazan fumarate (in Japanese), the Pharmaceuticals and Medical Devices Agency of Japan. 2014. Accessed 28 May 2015.
  21. 21.
    The interview form for vonoprazan fumarate (Takecab® tablets 10 mg and 20 mg) ver. 3, (in Japanese). Takeda Pharmaceutical Company Limited. 2015. Accessed 28 May 2015.
  22. 22.
    Prescribing information of Takecab® tablets 10 mg and 20 mg ver. 2 (in Japanese). 2015. Accessed 28 May 2015.
  23. 23.
    Arikawa Y, Nishida H, Kurasawa O, Hasuoka A, Hirase K, Inatomi N, Hori Y, Matsukawa J, Imanishi A, Kondo M, Tarui N, Hamada T, Takagi T, Takeuchi T, Kajino M. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). J Med Chem. 2012;55:4446–56.CrossRefPubMedGoogle Scholar
  24. 24.
    Shin JM, Inatomi N, Munson K, Strugatsky D, Tokhtaeva E, Vagin O, Sachs G. Characterization of a novel potassium-competitive acid blocker of the gastric H, K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther. 2011;339:412–20.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Hori Y, Imanishi A, Matsukawa J, Tsukimi Y, Nishida H, Arikawa Y, Hirase K, Kajino M, Inatomi N. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther. 2010;335:231–8.CrossRefPubMedGoogle Scholar
  26. 26.
    US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry, drug interaction studies: study design, data analysis, implications for dosing, and labeling recommendations. 2012. Accessed 26 Aug 2015.
  27. 27.
    European Medicine Agency (EMA), Committee for Human Medicinal Products (CHMP). Guideline on the investigation of drug interactions. 2012. Accessed 26 Aug 2015.
  28. 28.
    Ogawa R, Echizen H. Drug-drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet. 2010;49:509–33.CrossRefPubMedGoogle Scholar
  29. 29.
    Matsukawa J, Hori Y, Nishida H, Kajino M, Inatomi N. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol. 2011;81:1145–51.CrossRefPubMedGoogle Scholar
  30. 30.
    Sandvik AK, Brenna E, Waldum HL. Review article: the pharmacological inhibition of gastric acid secretion-tolerance and rebound. Aliment Pharmacol Ther. 1997;11:1013–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Freston JW. Omeprazole, hypergastrinemia, and gastric carcinoid tumors. Ann Intern Med. 1994;121:232–3.CrossRefPubMedGoogle Scholar
  32. 32.
    Klinkenberg-Knol EC, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology. 2000;118:661–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Department of PharmacotherapyMeiji Pharmaceutical UniversityKiyoseJapan

Personalised recommendations